Nanoparticles beyond the blood-brain barrier for glioblastoma

Jena, Lynn; Dunne, Nicholas; McCarthy, Helen

doi:10.1016/b978-0-12-821567-8.00027-0

Cited by 1 publication

(1 citation statement)

References 233 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using polymeric nanoparticles (NPs) is another promising therapeutic method [ 204 , 205 ]. NPs are carriers with diameters ranging from 10 to 1000 nm that can be engineered from various materials, including metal-, lipid-, and polymer-based materials.…”

Section: Blood–brain Barrier (Bbb) In Gbmmentioning

confidence: 99%

Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers

Rabah,

Ait Mohand,

Kravchenko-Balasha

2023

IJMS

View full text Add to dashboard Cite

The most prevalent and aggressive type of brain cancer, namely, glioblastoma (GBM), is characterized by intra- and inter-tumor heterogeneity and strong spreading capacity, which makes treatment ineffective. A true therapeutic answer is still in its infancy despite various studies that have made significant progress toward understanding the mechanisms behind GBM recurrence and its resistance. The primary causes of GBM recurrence are attributed to the heterogeneity and diffusive nature; therefore, monitoring the tumor’s heterogeneity and spreading may offer a set of therapeutic targets that could improve the clinical management of GBM and prevent tumor relapse. Additionally, the blood–brain barrier (BBB)-related poor drug delivery that prevents effective drug concentrations within the tumor is discussed. With a primary emphasis on signaling heterogeneity, tumor infiltration, and computational modeling of GBM, this review covers typical therapeutic difficulties and factors contributing to drug resistance development and discusses potential therapeutic approaches.

show abstract

Section: Blood–brain Barrier (Bbb) In Gbmmentioning

confidence: 99%